Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a clinical phase I/IIa study, subcutaneous injections of the peptide FOL-005 increased hair growth by 8% and were safe for treating alopecia.

This study found that repeatedly collecting hair follicles from individuals with fragile X syndrome is feasible for measuring FMR1 and FMRP levels in both home and office settings.

This study reported that Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology significantly improved hair thickness, density, shine, and elasticity, while reducing hair loss by an average of 66.8% and enhancing hair growth by up to 32.5% in subjects with androgenic alopecia over nine months.

This case report describes a 50-year-old woman with frontal fibrosing alopecia who showed no improvement despite multiple treatments, including intralesional triamcinolone and topical glucocorticoids.

This study presents cases suggesting that hair transplantation may trigger de novo frontal fibrosing alopecia in some patients, highlighting a potential association worth considering as cosmetic hair procedures become more common.

This study found that conditional deletion of Mof in mice resulted in severe defects in skin development, including compromised epidermal differentiation and hair growth, leading to perinatal lethality.

This case report observed no hair regrowth after treating a woman with postmenopausal frontal fibrosing alopecia using systemic and local corticosteroids, suggesting the need for more innovative therapies.

This case report documents the first known instance of FOXN1 duplication linked to congenital hypertrichosis.

Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.

This study observed that the osteopontin-derived peptide FOL-005 inhibited hair growth in human scalp skin models, contrary to its hair growth promotion in mice, supporting further clinical testing for excessive hair growth treatment.

This study reported no significant improvement in patients with frontal fibrosing alopecia treated with various therapeutic agents, highlighting the need for more evidence-based treatments, especially in those with active disease.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This review discusses the current understanding of frontal fibrosing alopecia's pathogenesis, highlighting genetic susceptibility, immune response involvement, and possible links to steroid hormones, but reports no new clinical results.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This review discusses the various treatment options for frontal fibrosing alopecia but reports no definitive results, as no treatment has proven effective in halting hairline recession or promoting hair growth.

This study adds evidence suggesting a genetic component to frontal fibrosing alopecia, with daughters experiencing an earlier onset than their mothers, although the clinical pattern remains similar to non-familial cases.

This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.

This study found that the FOS gene may play a significant role in promoting hair follicle development in Tan sheep, with elevated expression during the Er-mao period.

5% minoxidil foam helps women with thinning hair.

This article discusses the FOXTM Procedure's potential impact on hair restoration surgery, noting that its long-term effects are not yet clear and reports no new clinical findings.

Advanced fluorescence technology effectively treats skin discoloration from certain creams.

This paper reviews the evolution and classification of forehead reduction and orbital contouring techniques in transgender females, but reports no new clinical findings.

In this case report, topical application of fluocinolone acetonide acetate ointment increased hair length and thickness in three family members with congenital hypotrichosis.

This review hypothesizes that excessive facial photo-protection may contribute to frontal fibrosing alopecia by disrupting immunological homeostasis through the aryl hydrocarbon receptor-kynurenine pathway, but it reports no new clinical results.

This case report describes a patient with a severe pruritic rash and hair loss in both axillary regions, with no fluorescence under a Wood's lamp and hair follicle-centred papules observed through dermoscopy.

This review discusses the etiology, pathogenesis, clinical presentation, and treatment of frontal fibrosing alopecia, noting the lack of clinical trial data and limited observational treatment results.

This review discusses the pedicled temporoparietal fascial flap for head and neck reconstruction, detailing its anatomy, technique, complications, and sustained relevance despite newer microvascular methods; it reports no new clinical results.

This piece discusses the benefits of head support during follicular unit extraction in a seated position and reports no new clinical results; the authors suggest an ergonomic support system to improve graft quality.

This case report describes a 66-year-old man with frontal fibrosing alopecia, a rare lichen planopilaris variant, presenting with scarring alopecia at the hairline and extensive body hair loss.

This article discusses the connection between product use, contact dermatitis, and frontal fibrosing alopecia and reports no new findings; the authors emphasize the need for more research to improve patient outcomes.